Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open-angle glaucoma without pseudoexfoliation or pigment dispersion component;~* Either two or more years of dosing with Travatan, or no prior exposure (less than 1 month) to a topical ocular prostaglandin;~* Requires a trabeculectomy;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Pseudoexfoliation or pigment dispersion;~* History of chronic or recurrent severe inflammatory eye disease;~* History of or current ocular infection or ocular inflammation within the past 3 months in either eye;~* Greater than one month but less than two years of exposure to TRAVATAN;~* Pregnant, breast-feeding, not using highly effective birth control;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRAVATAN (Type: None): As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
- Treatment Naive (Type: None): No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue

Based on this trial design, predict the completion outcome and termination type (if applicable).